EZH2 and colorectal cancer: Conversely, a recent meta-analysis of 8 studies comprised of 1059 patients with colorectal cancer concluded that higher EZH2 expression evaluated by immunohistochemistry was associated with significantly improved overall survival [HR = 0.58, CI 95% (0.38–0.79)], suggesting that in patients with colorectal cancer, EZH2 may function as a tumor suppressor [14].